-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabozantinib S-malate in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabozantinib S-malate in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sonrotoclax in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sonrotoclax in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sonrotoclax in Myelodysplastic Syndrome Drug Details: Sonrotoclax is under development for the...
-
Product Insights
Cutaneous Lupus Erythematosus – Drugs In Development, 2023
Global Markets Direct’s, ‘Cutaneous Lupus Erythematosus - Drugs In Development, 2023’, provides an overview of the Cutaneous Lupus Erythematosus pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cutaneous Lupus Erythematosus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Hematopoietic Stem Cell Transplantation – Drugs In Development, 2023
Global Markets Direct’s, ‘Hematopoietic Stem Cell Transplantation - Drugs In Development, 2023’, provides an overview of the Hematopoietic Stem Cell Transplantation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hematopoietic Stem Cell Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Secondary Acute Myeloid Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Secondary Acute Myeloid Leukemia - Drugs In Development, 2023’, provides an overview of the Secondary Acute Myeloid Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Secondary Acute Myeloid Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Subacute Cutaneous Lupus Erythematosus (SCLE) – Drugs In Development, 2023
Global Markets Direct’s, ‘Subacute Cutaneous Lupus Erythematosus (SCLE) - Drugs In Development, 2023’, provides an overview of the Subacute Cutaneous Lupus Erythematosus (SCLE) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Subacute Cutaneous Lupus Erythematosus (SCLE), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Mediastinal B-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Primary Mediastinal B-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Mediastinal B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MP-0310 in Cervical Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MP-0310 in Cervical Cancer Drug Details: MP-0310 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6289 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6289 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RG-6289 in Alzheimer's DiseaseDrug Details:RG-6289 is under development for the treatment of Alzheimer's...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mocravimod Hydrochloride in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mocravimod Hydrochloride in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mocravimod Hydrochloride in Ulcerative Colitis Drug Details: Mocravimod hydrochloride (KRP-203) is...